Welcome to our dedicated page for Intellia Therape SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intellia Therapeutics, Inc. (NASDAQ: NTLA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Current Reports on Form 8-K that detail material events in its clinical and corporate development. As a clinical-stage gene editing company, Intellia uses SEC filings to report key information about its CRISPR-based programs, financial results and significant regulatory interactions.
Recent 8-K filings furnished by Intellia describe positive Phase 1 and Phase 1/2 data for its investigational in vivo CRISPR therapies, nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). These filings summarize trial designs, patient numbers, biomarker reductions, clinical outcome measures and safety observations over multi-year follow-up. Other 8-Ks discuss the initiation and status of global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO, as well as the FDA’s clinical hold on the MAGNITUDE programs for nex-z.
Intellia also uses Form 8-K to furnish quarterly financial results, including collaboration revenue, research and development expenses, general and administrative expenses and cash, cash equivalents and marketable securities. Additional filings report equity inducement grants made under the company’s 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4), and changes involving senior executives.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that highlight the most important points in dense regulatory documents. Users can quickly understand the implications of Intellia’s 8-K disclosures, track the evolution of its nex-z and lonvo-z programs, and monitor material events that may affect NTLA’s risk profile and development timeline.
LEONARD JOHN M reported acquisition or exercise transactions in this Form 4 filing.
Intellia Therapeutics, Inc. President and CEO John M. Leonard reported equity awards and updated his holdings. He received a stock option for 225,400 shares of common stock, granted at a price of $0.00 per share. He was also granted 156,400 shares of common stock in the form of restricted stock units, each representing a contingent right to receive one share of Intellia common stock. The option was granted on March 1, 2026, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. After these awards, he directly owned 1,169,739 shares of common stock and indirectly held 58,415 shares through the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics EVP and General Counsel James Basta reported routine equity compensation changes and a small tax-related share sale. On March 1, 2026, he received a grant of 65,829 stock options and 46,080 shares of common stock as equity awards. The option grant vests 33% on January 1, 2027, with the remaining 67% vesting in 24 equal monthly installments after that date. On March 2, 2026, 1,211 shares of common stock were sold at $13.78 per share in a mandatory sell-to-cover transaction to satisfy tax withholding on vested restricted stock units, described as not a voluntary trade by the reporting person.
Intellia Therapeutics executive vice president and chief medical officer David Lebwohl reported equity awards on Common Stock and stock options. On March 1, 2026, he acquired stock options for 14,204 shares at an exercise price of
He also acquired 9,943 shares of Common Stock at
Dulac Edward J III reported acquisition or exercise transactions in this Form 4 filing.
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported new equity awards. On
The option was granted with 33% vesting on
Intellia Therapeutics EVP and Chief Scientific Officer Birgit C. Schultes received new equity awards. On March 1, 2026, she was granted stock options for 56,000 shares of Intellia common stock at an exercise price of $0.00 per share and 39,200 shares of common stock as a grant.
The common stock grant is based on restricted stock units, each representing a contingent right to receive one share of Intellia common stock. The option grant vests with 33% on January 1, 2027, and the remaining 67% in 24 substantially equal monthly installments after that date.
Intellia Therapeutics EVP and Chief Technical Officer Eliana Clark reported a mix of equity awards and a small tax-related sale. Clark received 7,353 shares of common stock from a grant of restricted stock units and a stock option for 10,505 shares. On a separate date, 607 shares were automatically sold at
Intellia Therapeutics VP and Chief Accounting Officer Michael P. Dube received an equity award in the form of restricted stock units. On the reported date, he acquired 17,250 shares of Intellia common stock through a grant, at a stated price of $0.00 per share.
The award is structured as restricted stock units, each representing a contingent right to receive one share of Intellia common stock. Following this grant, Dube’s directly held common stock position reported in this filing increased to 69,527 shares.
Intellia Therapeutics, Inc. is offering up to
The prospectus supplement states sales may be made from time to time on the Nasdaq Global Market (symbol NTLA); shares outstanding were 116,317,060 as of
Intellia Therapeutics expanded its at-the-market stock offering program with Jefferies, increasing capacity from
Separately, the FDA removed the clinical hold on the MAGNITUDE Phase 3 trial of nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy after prior Grade 4 liver enzyme elevations. Intellia and the FDA agreed on added liver and cardiac safety exclusions and enhanced monitoring, allowing enrollment activities in both MAGNITUDE and MAGNITUDE-2 to resume.
Intellia Therapeutics is a genome-editing biotech developing in vivo CRISPR medicines, led by two Phase 3 programs. Lonvoguran ziclumeran (lonvo-z, NTLA-2002) targets hereditary angioedema with a one-time IV treatment; the HAELO Phase 3 trial fully enrolled 80 patients, with topline data expected by mid-2026 and a planned U.S. launch in the first half of 2027, following a BLA filing in the second half of 2026.
Nexiguran ziclumeran (nex-z, NTLA-2001) targets ATTR amyloidosis. The MAGNITUDE Phase 3 cardiomyopathy trial is on FDA clinical hold after a case of severe liver injury and a subsequent patient death, while the FDA has lifted the hold on the MAGNITUDE-2 Phase 3 polyneuropathy trial. Earlier Phase 1 data showed deep, durable TTR reductions and signs of disease stabilization. Intellia also advances additional CRISPR and cell-therapy collaborations, including a co-development deal with Regeneron and licensed ex vivo programs, and highlights extensive regulatory, manufacturing, competition and IP risks typical for first-wave CRISPR therapies.